Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis.
Jamie L WagnerBruce M JonesKayla R StoverJohn D ClearyChristopher M BlandKatie E SchipperDaniel B ChastainKatie E BarberPublished in: Open forum infectious diseases (2024)
Daptomycin use for gram-positive infections has increased. This cost minimization analysis aimed to determine cost and/or time savings of daptomycin over vancomycin. The estimated hospital cost savings was US$166.41 per patient, and pharmacist time saved of almost 20 minutes per patient. Daptomycin has the potential to save both time and money.